Asia-Pacific Biologics Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jan 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 196
  • No of Figures: 52

Asia-Pacific Biologics Market, By Class (Tumor Necrosis Factor-Α (TNF) Inhibitors, B-Cell Inhibitors, Interleukin Inhibitors, Selective Co-Stimulation Modulators (Abatacept), Others), Type (Monoclonal Antibodies (mAbs), Therapeutic Proteins, Vaccines, Cellular—Based Biologics, Gene Based Biologics, Other Products), Route of Administration (Injection, Infusion), Application (Oncology, Autoimmune diseases, Diabetes, Infectious Diseases, Cardiovascular Diseases, Ophthalmic Conditions, Dermatological Diseases, Others), Drug Classification (Branded Drugs, Generic Drugs), Source Material (Humans, Avian Cell Culture, Yeast, Bacteria, Insect Cell Culture, Transgenics), End User( Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2029.

Asia-Pacific Biologics Market

Market Analysis and Insights: Asia-Pacific Biologics Market

Asia-Pacific biologics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.5% in the forecast period of 2022 to 2029 and is expected to reach USD 130,466.91 million by 2029 from USD 53,903.20 million in 2021. The market for biologics is expected to grow in the forecast year for several reasons, including the increase in prevalence of chronic diseases such as diabetes and cancer.

Biologics are the drugs produced from living organisms or some components of living organisms. These drugs can be derived from different biological sources, including humans, avian cell culture, yeast, bacteria, and insect cell culture. These drugs involve therapeutic proteins, monoclonal antibodies, and vaccines. These drugs can be used to treat different types of chronic conditions, including cancers, inflammatory diseases, metabolic diseases, cardiovascular diseases, and infectious diseases.

Biologic drugs have several advantages compared to other drug types, including small molecules. These are very much target-specific which has enhanced its demand among healthcare professionals. Moreover, the side effects caused are mostly related to exaggerated pharmacological effects, leading to mild health effects. Biologic drugs have also been proved to hold high potential for several therapeutic areas and have revolutionized treatments of several serious illnesses. For instance, Rituximab (chimeric monoclonal antibody) has significantly improved non-Hodkings lymphoma.

Moreover, recent advancements in biologics are also accelerating the market’s growth. Rising healthcare expenditure is another factor that is anticipated to foster the market’s growth. However, a lack of skilled and trained professionals and stringent regulatory processes may restrain the market’s growth.

This biologics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the nut oil market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Biologics Market

Asia-Pacific Biologics Market Scope and Market Size

Asia-Pacific biologics market is segmented into eight notable segments based on class, type, route of administration, application, drug classification, source material, end user and distribution channel.

  • On the basis of class, the Asia-Pacific biologics market is segmented into tumor necrosis factor-Α (TNF) inhibitors, B-cell inhibitors, interleukin inhibitors, selective co-stimulation modulators (Abatacept), others. In 2022, tumor necrosis factor-A (TNF) inhibitors is expected to dominate the Asia-Pacific biologics market due to the increasing prevalence of inflammatory diseases including plaque psoriasis, rheumatoid arthritis among others and presence of pipeline therapies.
  • On the basis of type, the Asia-Pacific biologics market is segmented into monoclonal antibodies (MABS), therapeutic proteins, vaccines, cellular—based biologics, gene based biologics, and other products. In 2022, monoclonal antibodies are expected to dominate the Asia-Pacific biologics market due to rising preference for biological therapies and increasing usage of monoclonal antibodies for COVID-19 treatment is also accelerating the market growth.
  • On the basis of route of administration, the Asia-Pacific biologics market is segmented into injection and infusion. In 2022, injection segment is expected to dominate the Asia-Pacific biologics market due to protein nature of most of the biologics drugs which allows high absorption by the human body.
  • On the basis of application, the Asia-Pacific biologics market is segmented into oncology, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases, ophthalmic diseases, dermatological diseases and others. In 2022, the oncology segment is expected to dominate the Asia-Pacific biologics market due to the rising prevalence of cancer and the growing effectiveness of biologics for cancer treatment.
  • On the basis of drug classification, the Asia-Pacific biologics market is segmented into branded and generics. In 2022, the prostate cancer segment is expected to dominate the Asia-Pacific biologics market as biologics are patented, and thus, most of the market is occupied with branded biologics drugs.
  • On the basis of source material, the Asia-Pacific biologics market is segmented into humans, avian cell culture, yeast, bacteria, insects cell culture, and transgenics. In 2022, the bacteria segment is expected to dominate the Asia-Pacific biologics market due to rising demand for advanced and effective drugs and rising demand for rapid manufacturing processes that can yield in organisms with shot life span.
  • On the basis of end user, the Asia-Pacific biologics market is segmented into hospitals, specialty clinics and others. In 2022, the hospitals segment is expected to dominate the Asia-Pacific biologics market due to certified and trained healthcare professionals.
  • On the basis of distribution channel, the Asia-Pacific biologics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In 2022, the hospital pharmacies segment is expected to dominate the Asia-Pacific biologics market as most of the patients visit hospital pharmacies to procure branded biologics drugs. Moreover, increasing number of patient’s visits to hospitals is also increasing the drug sales at hospital pharmacies.

Asia-Pacific Biologics Market

Asia-Pacific Biologics Market Country Level Analysis

Asia-Pacific biologics market analyses market size information is on based on the basis of class, type, route of administration, application, drug classification, source material, end user, and distribution channel.

The countries covered in the Asia-Pacific biologics market report are China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam and Rest of Asia-Pacific.

China is expected to dominate the Asia-Pacific biologics market, followed by Japan and India, due to rising strategic initiatives by market players and increasing regulatory approvals due to shortening regulatory pathways and rising preference for biologics drugs. Japan is projected to dominate due to increase in prevalence of chronic diseases such as diabetes and cancers. However, India is anticipated to dominate due to lifestyle changes in the country

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data. 

Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Asia-Pacific Biologics Market

Asia-Pacific biologics market also provides you with detailed market analysis for every country growth in biologics industry with its treatment sales, impact of advancement in the biologics market and changes in regulatory scenarios with their support for the Asia-Pacific biologics market.

Competitive Landscape and Asia-Pacific Biologics Market Share Analysis

Asia-Pacific biologics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Asia-Pacific biologics market.

Some of the major players operating in this market are Biocon, BeiGene, Bharat Biotech, KM Biologics (A Subsidiary of Meiji Holdings Co., Ltd.), Shanghai Henlius Biotech, Inc., Biogen, BioDiem, Intas Pharmaceutical Ltd, YL Biologics, Innovent, FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., Qilu Pharmaceutical Co., Ltd., Ipsen Pharma, AGC Biologics, Panacea Biotec, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Chime Biologics, Catalent, Inc., NBHL ltd., Cipla Inc., Celltrion Healthcare Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, AbbVie Inc., Bristol-Myers Squibb Company, WuXi Biologics, Johnson & Johnson Services, Inc., Evotech, Samsung Biologics among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the Asia-Pacific biologics market.

  • In November 2021, Biocon has launched Interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection in collaboration with Viatris Inc. The new product launched helped patients control high blood sugar in adults and pediatric patients suffering from diabetes 1 and diabetes 2.
  • In December 2019, Bharat Biotech launched ROTAVAC 5D-lowest dose volume rotavirus vaccine across the world. The product launch has been developed under the partnership with the Department of Biotechnology, Government of India.

Collaboration, joint ventures and other strategies by the market player is enhancing the company in the biologics market which also provides the benefit for organisation to improve their offering for medications.

Customization Available: Asia-Pacific Biologics Market 

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.  


SKU-

TABLE 1 PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT COUNTRIES

TABLE 3 ASIA-PACIFIC BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 4 ASIA-PACIFIC TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 5 ASIA-PACIFIC B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 6 ASIA-PACIFIC INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 7 ASIA-PACIFIC BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 8 ASIA-PACIFIC BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 9 ASIA-PACIFIC BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 10 ASIA-PACIFIC BIOLOGICS MARKET, BY TYPE , 2020-2029 (USD MILLION)

TABLE 11 ASIA-PACIFIC MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 12 ASIA-PACIFIC THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 13 ASIA-PACIFIC VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 14 ASIA-PACIFIC BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 ASIA-PACIFIC ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 16 ASIA-PACIFIC AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 17 ASIA-PACIFIC BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 ASIA-PACIFIC BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 19 ASIA-PACIFIC BIOLOGICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 20 CHINA BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 21 CHINA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 22 CHINA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 23 CHINA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 24 CHINA BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 CHINA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 26 CHINA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 27 CHINA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 28 CHINA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 29 CHINA BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 30 CHINA BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 31 CHINA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 32 CHINA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 33 CHINA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 34 CHINA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 35 CHINA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 36 JAPAN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 37 JAPAN TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 38 JAPAN B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 39 JAPAN INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 40 JAPAN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 JAPAN MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 JAPAN THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 43 JAPAN VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 44 JAPAN BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 45 JAPAN BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 46 JAPAN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 JAPAN ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 48 JAPAN AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 49 JAPAN BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 50 JAPAN BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 51 JAPAN BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 INDIA BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 53 INDIA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 54 INDIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 55 INDIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 56 INDIA BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 57 INDIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 58 INDIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 59 INDIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 INDIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 61 INDIA BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 62 INDIA BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 63 INDIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 64 INDIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 65 INDIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 66 INDIA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 67 INDIA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 68 AUSTRALIA BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 69 AUSTRALIA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 70 AUSTRALIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 71 AUSTRALIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 72 AUSTRALIA BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 73 AUSTRALIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 74 AUSTRALIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 75 AUSTRALIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 76 AUSTRALIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 77 AUSTRALIA BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 78 AUSTRALIA BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 79 AUSTRALIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 80 AUSTRALIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 81 AUSTRALIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 82 AUSTRALIA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 83 AUSTRALIA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 84 SOUTH KOREA BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 85 SOUTH KOREA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 86 SOUTH KOREA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 87 SOUTH KOREA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 88 SOUTH KOREA BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 89 SOUTH KOREA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 90 SOUTH KOREA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 91 SOUTH KOREA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 92 SOUTH KOREA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 93 SOUTH KOREA BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 94 SOUTH KOREA BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 95 SOUTH KOREA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 96 SOUTH KOREA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 97 SOUTH KOREA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 98 SOUTH KOREA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 99 SOUTH KOREA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 100 SINGAPORE BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 101 SINGAPORE TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 102 SINGAPORE B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 103 SINGAPORE INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 104 SINGAPORE BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 105 SINGAPORE MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 106 SINGAPORE THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 107 SINGAPORE VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 108 SINGAPORE BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 109 SINGAPORE BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 110 SINGAPORE BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 111 SINGAPORE ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 112 SINGAPORE AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 113 SINGAPORE BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 114 SINGAPORE BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 115 SINGAPORE BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 116 MALAYSIA BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 117 MALAYSIA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 118 MALAYSIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 119 MALAYSIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 120 MALAYSIA BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 121 MALAYSIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 122 MALAYSIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 123 MALAYSIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 124 MALAYSIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 125 MALAYSIA BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 126 MALAYSIA BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 127 MALAYSIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 128 MALAYSIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 129 MALAYSIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 130 MALAYSIA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 131 MALAYSIA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 132 INDONESIA BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 133 INDONESIA TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 134 INDONESIA B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 135 INDONESIA INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 136 INDONESIA BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 137 INDONESIA MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 138 INDONESIA THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 139 INDONESIA VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 140 INDONESIA BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 141 INDONESIA BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 142 INDONESIA BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 143 INDONESIA ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 144 INDONESIA AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 145 INDONESIA BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 146 INDONESIA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 147 INDONESIA BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 148 THAILAND BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 149 THAILAND TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 150 THAILAND B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 151 THAILAND INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 152 THAILAND BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 153 THAILAND MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 154 THAILAND THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 155 THAILAND VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 156 THAILAND BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 157 THAILAND BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 158 THAILAND BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 159 THAILAND ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 160 THAILAND AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 161 THAILAND BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 162 THAILAND BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 163 THAILAND BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 164 PHILIPPINES BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 165 PHILIPPINES TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 166 PHILIPPINES B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 167 PHILIPPINES INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 168 PHILIPPINES BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 169 PHILIPPINES MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 170 PHILIPPINES THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 171 PHILIPPINES VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 172 PHILIPPINES BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 173 PHILIPPINES BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 174 PHILIPPINES BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 175 PHILIPPINES ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 176 PHILIPPINES AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 177 PHILIPPINES BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 178 PHILIPPINES BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 179 PHILIPPINES BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 180 VIETNAM BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 181 VIETNAM TUMOR NECROSIS FACTOR-Α (TNF) INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 182 VIETNAM B-CELL INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 183 VIETNAM INTERLEUKIN INHIBITORS IN BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

TABLE 184 VIETNAM BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 185 VIETNAM MONOCLONAL ANTIBODIES (MABS) IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 186 VIETNAM THERAPEUTIC PROTEINS IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 187 VIETNAM VACCINES IN BIOLOGICS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 188 VIETNAM BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 189 VIETNAM BIOLOGICS MARKET, BY DRUG CLASSIFICATION, 2020-2029 (USD MILLION)

TABLE 190 VIETNAM BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 191 VIETNAM ONCOLOGY IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 192 VIETNAM AUTOIMMUNE DISEASES IN BIOLOGICS MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 193 VIETNAM BIOLOGICS MARKET, BY SOURCE MATERIAL, 2020-2029 (USD MILLION)

TABLE 194 VIETNAM BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 195 VIETNAM BIOLOGICS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 196 REST OF ASIA-PACIFIC BIOLOGICS MARKET, BY CLASS, 2020-2029 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions